Monoclonal immunoglobulins and peripheral neuropathy: Causative agent or coincidental finding?

Clinical Lymphoma

Volumn 5, Issue 3, 2004, Pages 172-173

  Owen, Roger G ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AUTOANTIBODY; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GM1; GANGLIOSIDE GM2; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY; MYELIN ASSOCIATED GLYCOPROTEIN; PARAPROTEIN; PURINE DERIVATIVE; RITUXIMAB; SULFATIDE;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW EXAMINATION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DIFFERENTIAL DIAGNOSIS; FREQUENCY ANALYSIS; HUMAN; MEDICAL DECISION MAKING; MONOCLONAL IMMUNOGLOBULINEMIA; NOTE; PATHOGENESIS; PERIPHERAL NEUROPATHY; PROTEIN BLOOD LEVEL; WALDENSTROEM MACROGLOBULINEMIA;

EID: 13644257396     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-9655(11)70076-8     Document Type: Note

References (22)

1. Stone MJ, McElroy YG, Pestronk A, et al. Human monoclonal macroglobulins with antibody activity. Semin Oncol 2003; 30:318-324.
2. Lopate G, Choksi R, Pestronk A. Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies. Muscle Nerve 2002; 25:828-836.
3. Eurelings M, Ang CW, Notermans NC, et al. Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy. Neurology 2001; 57:1909-1912.
4. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18:214-226.
5. Erb S, Ferracin F, Fuhr R et al. Polyneuropathy attributes: a comparison between patients anti-MAG and anti-sulfatide antibodies. J Neurol 2000; 247:767-772.
6. Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. J Clin Oncol 1993; 11:914-920.
7. Owen RG, Barrans SL, Richards SJ, et al. Waldenström macroglobulinemia: development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 2001; 116:420-428.
8. Nobile-Orazio E, Casellato C, Di Troia A. Neuropathies associated with IgG and IgA monoclonal gammopathy. Rev Neurol (Paris) 2002; 158:979-987.
9. Hughes RA. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy. Rev Neurol (Paris) 2002; 158:32-36.
10. Di Troia A, Carpo M, Meucci N, et al. Clinical features and anti-neural activity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J Neurol Sci 1999; 164:64-71.
11. Favereaux A, Lagueny A, Vital A, et al. Serum IgG antibodies to P0 dimer and 35kDa P0 related protein in neuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 2003; 74:1262-1266.
12. Owen RG, Parapia LA, Higginson J, et al. Clinicopathological correlates of IgM paraproteinemias. Clin Lymphoma 2000; 1:39-43.
13. Wicklund MP, Kissel JT. Paraproteinemic neuropathy. Curr Treat Options Neurol 2001; 3:147-156.
14. Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:121-126.
15. Owen RG, Johnson SA, Morgan GJ. Waldenström's macroglobulinaemia: laboratory diagnosis and treatment. Hematol Oncol 2000; 18:41-49.
16. Owen RG. Treatment options in Waldenstrom's macroglobulinaemia: the role of the purine analogues. Expert Opin Pharmacother 2001; 2:945-952.
17. Kyle RA, Therneau TM, Rajkumar SV, et al. Long term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102:3759-3764.
18. Oksenhendler E, Chevret S, Leger JM, et al. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 1995; 59:243-247.
19. Gorson KC, Ropper AH, Weinburg DH, et al. Treatment experience with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 2001; 24:778-786.
20. Wilson HC, Lunn MP, Schey S, et al. Successful treatment of IgM paraproteinemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 1999; 66:575-580.
21. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74:485-489.
22. Rudnicki SA, Harik SI, Dhodapkar M, et al. Nervous system dysfunction in Waldenstrom's macroglobulinemia: response to treatment. Neurology 1998; 51:1210-1213.